Author | Matt Hoffman


The Importance of Patient-Centered Care in Parkinson Disease

September 22, 2020

The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers spoke to the importance of patient-focused interventions in PD.

Investigational Drug Targeting Epstein-Barr Virus Shows Promise for Progressive MS

September 21, 2020

Atara Biotherapeutics’ allogeneic EBV-targeted T-cell therapy, ATA188, is well-tolerated in phase 1, with a dose identified for the randomized placebo-controlled portion of the study.

Ganaxolone Meets Primary End Point in CDKL5 Deficiency Disorder Study

September 20, 2020

Marinus Pharmaceuticals’ positive allosteric GABAA receptor modulator ganaxolone was associated with significant median reductions in 28-day major motor seizure frequency compared to placebo.

Ocrelizumab Treatment Results in High NEDA Rates, Improvements in MS Symptoms

September 19, 2020

A pair of datasets from the phase 3b CASTING study of ocrelizumab (Ocrevus; Genentech) suggest that patients treated with the agent experienced high rates of no evidence of disease activity status regardless of prior DMT exposure.